Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

RALPH ALHALEL

Allopathic & Osteopathic Physicians Internal Medicine Gastroenterology

NPI
1700830353
CMS profile
32241
Location
MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$749.94

37 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $749.94 37

By paying entity

PY2019 · entire year · sorted by reported total

Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

RALPH ALHALEL

NPI 1700830353 · CMS profile ID 32241

Allopathic & Osteopathic Physicians / Internal Medicine / Gastroenterology

MCALLEN, TX

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
RALPH ALHALEL, NPI 1700830353, CMS profile ID 32241, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–37 of 37 matching records. This page contains 37 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1700830353?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

37 matching records · $749.94 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 37 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–37 of 37.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.4412/16/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619099 CMS
AbbVie, Inc. $16.4312/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647802113 CMS
AbbVie, Inc. $16.3812/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647802111 CMS
Takeda Pharmaceuticals U.S.A., Inc. $30.3412/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682065073 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.1911/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681981079 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $4.4010/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619095 CMS
Takeda Pharmaceuticals U.S.A., Inc. $16.8010/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682027731 CMS
Takeda Pharmaceuticals U.S.A., Inc. $6.5710/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681681571 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.7409/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681735827 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $12.7809/10/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619091 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.5609/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682088497 CMS
Intercept Pharmaceuticals, Inc. $87.4008/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 702060559 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.5408/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681859527 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.1008/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682089129 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $5.3608/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619087 CMS
Takeda Pharmaceuticals U.S.A., Inc. $19.0208/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681799201 CMS
Takeda Pharmaceuticals U.S.A., Inc. $2.5308/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682036109 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.4408/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681758167 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.3208/01/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682103333 CMS
Takeda Pharmaceuticals U.S.A., Inc. $10.4507/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681934659 CMS
Takeda Pharmaceuticals U.S.A., Inc. $12.9106/13/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681890389 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $83.0106/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619083 CMS
Takeda Pharmaceuticals U.S.A., Inc. $13.8405/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682023085 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $1.3804/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619069 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $0.9604/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619073 CMS
Salix Pharmaceuticals, a division of Bausch Health US, LLC $7.8804/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684619079 CMS
Takeda Pharmaceuticals U.S.A., Inc. $17.0404/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681948355 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.0604/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682004079 CMS
Gilead Sciences, Inc. $106.5403/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681470485 CMS
Takeda Pharmaceuticals U.S.A., Inc. $7.7903/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681989517 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.3402/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681866017 CMS
Takeda Pharmaceuticals U.S.A., Inc. $1.7602/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 682038809 CMS
Allergan Inc. $11.4102/26/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670017019 CMS
Janssen Biotech, Inc. $17.6602/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658299577 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.0901/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681687647 CMS
Dova Pharmaceuticals $113.6301/23/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 705229719 CMS
Takeda Pharmaceuticals U.S.A., Inc. $14.8501/15/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681685581 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $749.94 37
PY2020 $420.45 27
PY2021 $703.45 46
PY2022 $1,041.54 42
PY2023 $775.96 21
PY2024 $1,310.53 38
PY2025 $447.58 24

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $352,790.88 227
PY2024 Principal investigator $269,533.46 68
PY2023 Principal investigator $335,027.89 61
PY2022 Recipient $1.00 1
PY2022 Principal investigator $35,164.94 37
PY2021 Recipient $938.46 1
PY2021 Principal investigator $34,998.93 15
PY2020 Principal investigator $98,605.96 19
PY2019 Recipient $9,135.15 2
PY2019 Principal investigator $18,309.40 7

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2024

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

68 records in PY2024

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Braintree Laboratories, Inc. $45.00 12/31/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204914
Principal investigator 1 Braintree Laboratories, Inc. $2,304.90 12/31/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120205016
Principal investigator 1 Braintree Laboratories, Inc. $2,000.00 12/30/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204838
Principal investigator 1 Braintree Laboratories, Inc. $125.00 12/17/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204602
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 12/11/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125500554
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $675.00 12/11/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, PHASE 2 DOSE-RANGING STUDY TO EVALUATE THE EFFICACY AND SAFETY OF TAK-101 FOR THE PREVENTION OF GLUTEN-SPECIFIC T CELL ACTIVATION IN SUBJECTS WITH CELIAC DISEASE ON A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125500556
Principal investigator 1 Braintree Laboratories, Inc. $1,915.20 12/10/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120204504
Principal investigator 1 GlaxoSmithKline, LLC. $2,963.00 12/06/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1156001917
Principal investigator 1 GlaxoSmithKline, LLC. $2,963.00 12/06/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 STUDY TO EVA No dispute reported 06/30/2026 1156003083
Principal investigator 1 GlaxoSmithKline, LLC. $1,500.00 11/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLEDPHASE 2 STUDY TO EVALU No dispute reported 06/30/2026 1127525480
Principal investigator 1 GlaxoSmithKline, LLC. $1,000.00 11/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLEDPHASE 2 STUDY TO EVALU No dispute reported 06/30/2026 1127525482
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,500.00 11/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125499514
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $750.00 11/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125499516
Principal investigator 1 Genentech, Inc. $28,458.00 11/13/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384303
Principal investigator 1 Genentech, Inc. $400.00 11/01/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384287
Principal investigator 1 Braintree Laboratories, Inc. $35,750.00 10/29/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203656
Principal investigator 1 Genentech, Inc. $2,511.00 10/23/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384301
Principal investigator 1 GlaxoSmithKline, LLC. $2,000.00 10/17/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLEDPHASE 2 STUDY TO EVALU No dispute reported 06/30/2026 1127531896
Principal investigator 1 GlaxoSmithKline, LLC. $11,000.00 10/17/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A DOSE-FINDING, DOUBLE-BLIND, PLACEBO-CONTROLLEDPHASE 2 STUDY TO EVALU No dispute reported 06/30/2026 1127531898
Principal investigator 1 Braintree Laboratories, Inc. $125.00 10/14/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120203202
Principal investigator 1 Genentech, Inc. $6,696.00 10/11/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384297
Principal investigator 1 PFIZER INC. $500.00 10/04/2024 Non-covered Recipient Entity
Biopharma Informatic LLC
A RANDOMIZED DOUBLEBLIND PLACEBOCONTROLLED 52WEEK STUDY TO ASSESS THE EFFICACY AND SAFETY OF ETRASIMOD IN SUBJECTS WITH MODERATELY ACTIVE ULCERATIVE COLITIS No dispute reported 06/30/2026 1130946012
Principal investigator 1 Braintree Laboratories, Inc. $3,372.71 10/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202796
Principal investigator 1 Genentech, Inc. $1,674.00 10/02/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384291
Principal investigator 1 Braintree Laboratories, Inc. $250.00 09/25/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202608
Principal investigator 1 Braintree Laboratories, Inc. $1,915.20 09/13/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120202148
Principal investigator 1 Genentech, Inc. $1,600.00 09/04/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384271
Principal investigator 1 Genentech, Inc. $837.00 08/23/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384281
Principal investigator 1 Braintree Laboratories, Inc. $4,576.60 08/16/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201698
Principal investigator 1 Genentech, Inc. $837.00 08/16/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384251
Principal investigator 1 Genentech, Inc. $837.00 08/07/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384261
Principal investigator 1 Braintree Laboratories, Inc. $5,216.40 07/19/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC -- MCALLEN
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120201096
Principal investigator 1 Genentech, Inc. $7,533.00 07/10/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384277
Principal investigator 1 Braintree Laboratories, Inc. $295.00 06/19/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200586
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $1,408.00 06/19/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125492812
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $56.00 06/17/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125492744
Principal investigator 1 Braintree Laboratories, Inc. $250.00 06/06/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200396
Principal investigator 1 Braintree Laboratories, Inc. $11,275.30 06/06/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200398
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $12,427.00 06/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125492074
Principal investigator 1 Genentech, Inc. $200.00 05/22/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384225
Principal investigator 1 Genentech, Inc. $400.00 05/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384235
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $74.00 05/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125491134
Principal investigator 1 Genentech, Inc. $9,477.00 05/08/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384243
Principal investigator 1 Braintree Laboratories, Inc. $12,000.00 05/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200148
Principal investigator 1 Braintree Laboratories, Inc. $3,000.00 05/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A PHASE 3, Double-Blind, Randomized, Two-Phase, Active-Controlled Study to Evaluate the Efficacy and Safety of Tegoprazan in Patients with Erosive Esophagitis No dispute reported 06/30/2026 1120200150
Principal investigator 1 Genentech, Inc. $600.00 05/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384227
Principal investigator 1 Genentech, Inc. $200.00 05/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384231
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,980.00 05/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125490687
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 04/26/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125490319
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $10,927.00 04/26/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125490321
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $2,362.00 04/26/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125490323
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $944.00 04/26/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125490325
Principal investigator 1 Genentech, Inc. $400.00 04/12/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384241
Principal investigator 1 Genentech, Inc. $837.00 04/10/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384221
Principal investigator 1 Genentech, Inc. $5,859.00 04/03/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384223
Principal investigator 1 Genentech, Inc. $837.00 03/29/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384197
Principal investigator 1 Genentech, Inc. $2,500.00 03/22/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384205
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $48.00 03/15/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125488259
Principal investigator 1 Genentech, Inc. $2,808.00 03/13/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384213
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $944.00 03/06/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125487645
Principal investigator 1 Genentech, Inc. $800.00 02/21/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384209
Principal investigator 1 Genentech, Inc. $1,404.00 02/14/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384215
Principal investigator 1 Genentech, Inc. $400.00 02/09/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384201
Principal investigator 1 Eli Lilly and Company $2,440.15 02/08/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1137354432
Principal investigator 1 Genentech, Inc. $28,080.00 02/07/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384187
Principal investigator 1 Takeda Pharmaceuticals U.S.A., Inc. $3,260.00 02/02/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
A STUDY OF TAK-062 IN TREATMENT OF ACTIVE CELIAC DISEASE IN PARTICIPANTS ATTEMPTING A GLUTEN-FREE DIET No dispute reported 06/30/2026 1125484953
Principal investigator 1 Eli Lilly and Company $11,051.00 01/26/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC INC
A MULTICENTER, PHASE 3B, OPEN-LABEL, SINGLE-ARM STUDY TO INVESTIGATE BOWEL URGENCY AND ITS RELATIONSHIP WITH OTHER OUTCOME MEASURES IN ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS TREATED WITH MIRIKIZUMAB No dispute reported 06/30/2026 1137354772
Principal investigator 1 Genentech, Inc. $400.00 01/05/2024 Non-covered Recipient Entity
BIOPHARMA INFORMATIC LLC
Roche Cancer Screening Collection Study No dispute reported 06/30/2026 1133384179